GlassScriptPhysician profile
Preston Gardner
NPI 1861784449
$2,700.11
in general payments reported to CMS, 2019-2025
22 companies · $857 in 2025
The $857 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $99.65 · 2021: $90.79 · 2022: $230 · 2023: $366 · 2024: $167 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $487.62 | 2019-2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Mentor Worldwide LLC | $382.49 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander |
| Musculoskeletal Transplant Foundation INC. | $335.76 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $270.04 | 2022-2023 | Keytruda |
| Kerecis Limited | $262.72 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Sientra, INC. | $161.76 | 2019 | |
| Allergan, INC. | $138.04 | 2019 | |
| Abbvie INC. | $123.99 | 2019-2025 | |
| Smith+Nephew, INC. | $96.81 | 2020-2025 | Collagenase Santyl, Regranex |
| Organogenesis INC. | $84.17 | 2020-2022 | |
| Incyte Corporation | $72.18 | 2021-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $56.79 | 2021-2023 | Dupixent |
| Galderma Laboratories, L.P. | $51.00 | 2019 | |
| Ucb, INC. | $33.39 | 2024 | Bimzelx |
| Leo Pharma INC. | $26.46 | 2020-2023 | Adbry |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $24.56 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Polarityte, INC. | $22.31 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.23 | 2023 | Cyltezo |
| Lilly USA, LLC | $15.61 | 2022 | |
| Mayne Pharma Commercial LLC | $13.56 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.57 | 2019 | |
| Biofrontera INC. | $11.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Preston Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.